Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICI Rechallenge in Advanced NSCLC Long-Term Responders
NCT06388031Phase 2Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, tislelizumab, camrelizumab, toripalimab in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Started Aug 2024; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06388031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388031.